
Gilead Sciences (GILD) Stock Forecast & Price Target
Gilead Sciences (GILD) Analyst Ratings
Bulls say
Gilead Sciences is viewed positively because its core HIV franchise is delivering unusually strong momentum, with 3Q26 HIV sales of $6.25B and management raising FY26 HIV growth guidance to 12% from 9%-10%, supported by Biktarvy leadership and Yeztugo’s $305M launch traction. The company’s broader fundamentals are also improving as PrEP demand and channel mix lift revenue, total FY26 product sales guidance rises to $31.0-$31.3B, and durable cash generation is reinforced by $6.4B in cash and $5.0B in 3Q26 operating cash flow. Beyond HIV, Trodelvy is expanding in oncology, Yescarta/Tecartus infrastructure supports anito-cel, and a growing inflammation pipeline plus tuck-in acquisitions adds long-term diversification and optionality.
Bears say
Gilead Sciences is exposed to several fundamental pressures that support a negative outlook, led by generic HIV entrants, competition in HCV, and greater-than-expected pricing pressure across its core franchises. Its growth thesis also depends on newer assets, yet slower Yescarta uptake, failure to expand its label, or setbacks in oncology programs such as Trodelvy could leave estimates vulnerable, while legal and patent risks add further uncertainty. The company also faces potential cuts in federal HIV spending, clinical trial misses or safety concerns, and broader macro weakness, any of which could weigh on revenue durability and execution.
This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Gilead Sciences (GILD) Forecast
Gilead Sciences (GILD) Analyst Forecast & Price Prediction
Start investing in Gilead Sciences (GILD)
Order type
Buy in
Order amount
Est. shares
0 shares